Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer

NCT00364611 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Bevacizumab
DRUG: Docetaxel
DRUG: Trastuzumab

Sponsor

Sanofi